Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Context Therapeutics Inc. announced financial results for 2023, with cash reserves of $14.4 million. The company plans to file an IND for CTIM-76 by March 2024, targeting CLDN6-positive tumors. Recent highlights include amending collaboration terms with Integral Molecular, presenting promising preclinical data, and upcoming participation in the Needham Virtual Healthcare Conference.
Positive
Context Therapeutics Inc. has a solid financial position with $14.4 million in cash and cash equivalents as of December 31, 2023.
The company is progressing towards filing an IND for CTIM-76, a promising candidate for CLDN6-positive tumors, by the end of March 2024.
Context recently amended its collaboration agreement with Integral Molecular, reducing payment obligations and focusing on CTIM-76 development.
Preclinical data presented at the SITC 38th Annual Meeting showcased CTIM-76's potential in inducing tumor regressions in CLDN6-positive cancer models.
The Company reported a net loss of $24.0 million for 2023, mainly driven by increased R&D expenses for CTIM-76 and a decision to discontinue ONA-XR development.
Context expects its cash reserves to support operations until late 2024, providing financial stability for upcoming milestones.
Negative
The net loss of $24.0 million for 2023 represents a significant increase compared to $14.8 million in 2022, indicating growing expenses.
The decision to discontinue ONA-XR development might have implications on the company's pipeline diversification and future revenue streams.
The reduction in cash reserves from $35.5 million in 2022 to $14.4 million in 2023 raises concerns about the company's financial management and sustainability.
The financial results disclosed by Context Therapeutics Inc. indicate a substantial increase in R&D expenses, primarily due to the development of their lead clinical candidate, CTIM-76. This surge from $7.1 million to $17.8 million underscores the company's strategic pivot towards CTIM-76, especially after discontinuing ONA-XR. The decision to focus resources on a single candidate could streamline operations and potentially accelerate the path to market, but it also consolidates risk. Investors should note the reduction in cash from $35.5 million to $14.4 million year-over-year, which although anticipated to fund operations into late 2024, signals a critical need for additional capital or successful progression of CTIM-76 to maintain the company's trajectory.
The preclinical data presented for CTIM-76 at the SITC meeting is particularly noteworthy. Demonstrating higher potency compared to other CLDN6-targeted therapies could position CTIM-76 favorably in the competitive landscape of solid tumor treatments. The upcoming IND filing with the FDA is a pivotal step that will determine the future course of Context's operations. For stakeholders, the therapeutic's ability to address gynecologic and testicular cancers presents a significant market opportunity, provided clinical trials validate the preclinical results. The amendment of the licensing agreement with Integral Molecular to more favorable terms also reflects prudent management of financial obligations, which could improve Context's financial sustainability in the long term.
Context's strategic amendment of its agreement with Integral Molecular to reduce payment obligations suggests a focused approach to resource allocation. This move, coupled with the comparative potency of CTIM-76 against other CLDN6-targeted compounds, positions the company to potentially capture a niche in the solid tumor therapeutics market. However, the financial runway into late 2024 necessitates close monitoring of the IND filing's outcome and subsequent clinical trial progress. The biotech industry often sees volatility around such milestones and Context's stock could be subject to significant fluctuations based on the perceived success or failure of these events.
03/21/2024 - 07:43 AM
CTIM-76 IND filing on track for late March 2024
Cash and cash equivalents of $14.4 million as of December 31, 2023
Company expects its cash and cash equivalents will continue to fund operations into late 2024
PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the year ended December 31, 2023, and reported on recent and upcoming business highlights.
“During the fourth quarter of 2023, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody, toward a first-in-human clinical study. Preclinical data presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting highlighted the broad therapeutic potential of CTIM-76 when targeting CLDN6-positive tumors. The preclinical data further support CTIM-76’s differentiated product profile, including its potential to address limitations of first-generation CLDN6-targeted clinical-stage therapies,” said Martin Lehr, CEO of Context. “We look forward to filing an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration (“FDA”) by the end of March 2024 for CTIM-76. We then plan to initiate a Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers upon receiving IND clearance from the FDA.”
Fourth Quarter 2023 and Recent Corporate Highlights
In February 2024, Context amended its collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) to reflect updated financial terms to reduce various payment obligations and narrow the license grant to only cover CTIM-76. In November 2023, Context presented preclinical data at the SITC 38th Annual Meeting that demonstrated CTIM-76 was well tolerated and induced dose-proportional tumor regressions in xenograft models of CLDN6-positive cancer. Benchmarking studies were conducted to compare CTIM-76 to clones of other CLDN6 clinical-stage compounds, including TORL-1-23 and AMG-794. In these studies, CTIM-76 was potent across a wide range of CLDN6 expression profiles, whereas TORL-1-23 potency was limited to CLDN6-high expression. In addition, CTIM-76 demonstrated ten-fold higher potency than that of AMG-794 in in vitro cytotoxicity and cytokine activation assays. Upcoming Corporate Presentation
The Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 2:15 p.m. ET. Context will also participate in one-on-one meetings. Fiscal Year 2023 Financial Results
Cash and cash equivalents were $14.4 million at December 31, 2023, compared to $35.5 million at December 31, 2022. Acquired in-process research and development expense (“IPR&D”) was $0.5 million for 2022 and reflects the expense recognized related to a development milestone achieved under the collaboration and license agreement with Integral. There was no IPR&D expense recognized in 2023. Research and development (“R&D”) expenses were $17.8 million for 2023, as compared to $7.1 million for the same period in 2022. The increase in R&D expenses was driven by higher CTIM-76 contract manufacturing costs and preclinical costs as a result of ongoing IND-enabling studies and activities. This increase was partially offset by a decrease in onapristone extended release (“ONA-XR”) expenses, primarily due to the Company’s decision in March 2023 to discontinue the development of ONA-XR and focus on the development of CTIM-76. General and administrative expenses were $7.3 million for 2023, as compared to $7.8 million for the same period in 2022. The decrease was primarily driven by decreases in insurance expenses and other administrative costs, partially offset by an increase in professional fees. Other income was $1.1 million for 2023, as compared to $0.5 million for the same period in 2022, primarily due to higher interest income earned on cash and cash equivalent balances. Context reported a net loss of $24.0 million for 2023, as compared to $14.8 million for the same period in 2022. 2024 Cash Guidance
About Context Therapeutics ® www.contexttherapeutics.com or follow the Company on X (formerly Twitter ) and LinkedIn .
Forward-looking Statements
Context Therapeutics Inc. Condensed Statements of Operations (Unaudited) Year Ended December 31, 2023 2022 Operating Expenses Acquired in-process research and development $ - $ 500,000 Research and development 17,782,731 7,091,163 General and administrative 7,289,885 7,790,040 Loss from operations (25,072,616 ) (15,381,203 ) Other income (expense), net 1,108,405 545,264 Net loss $ (23,964,211 ) $ (14,835,939 ) Net loss per common share, basic and diluted ($ 1.50 ) ($ 0.93 ) Weighted average shares outstanding, basic and diluted 15,966,053 15,966,053 Context Therapeutics Inc. Condensed Balance Sheets Data (Unaudited) December 31, December 31, 2023 2022 Cash and cash equivalents $ 14,449,827 $ 35,497,445 Other assets 1,612,908 2,468,498 Total assets $ 16,062,735 $ 37,965,943 Total liabilities $ 4,191,715 $ 3,207,577 Total stockholders' equity 11,871,020 34,758,366 Total liabilities and stockholders' equity $ 16,062,735 $ 37,965,943
Media Contact: gmangiaracina@6degreespr.com
Investor Relations Contact: IR@contexttherapeutics.com
Context Therapeutics Inc. had $14.4 million in cash and cash equivalents as of December 31, 2023.
Context Therapeutics Inc. plans to file an IND for CTIM-76 by the end of March 2024.
Context Therapeutics Inc. recently amended its collaboration agreement with Integral Molecular to focus on CTIM-76 development.
Context Therapeutics Inc. reported a net loss of $24.0 million for 2023.
Context Therapeutics Inc. expects its cash reserves to fund operations into late 2024.
